Takes over as Chief Executive after AGM
PuriCore, an international company focused on protection against the spread of infectious pathogens, has announced that Alex Martin will be appointed to the Board as Chief Executive following the company’s Annual General Meeting on 18 June. Martin will join the company on 1 June to allow a smooth transition with the retiring CEO, Michael Ashton. He will be based at PuriCore’s headquarters in Malvern, PA, US.
Martin has more than 25 years’ experience having held senior positions in both private and public companies principally in the pharmaceutical and biopharmaceutical industry. He was previously Chief Executive of Affectis Pharmaceuticals, Chief Operating Officer of Intercept Pharmaceuticals, and Chief Business Officer at Bioxell, which was acquired by Cosmo Pharmaceuticals. He began his career at SmithKline Beecham Pharmaceuticals before joining Novartis as Vice President, Global Business Development & Licensing. Most recently, he was President at moksha8, a Latin American specialist pharmaceutical company.